ALC
USDAlcon Inc. Ordinary Shares
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$72.510
Haut
$74.005
Bas
$72.090
Volume
1.72M
Fondamentaux de l'Entreprise
Capitalisation Boursière
36.6B
Industrie
Medical Instruments & Supplies
Pays
Switzerland
Statistiques de Trading
Volume Moyen
2.25M
Bourse
NYQ
Devise
USD
Intervalle sur 52 Semaines
Actualités Connexes
Broadwood Partners Condemns Alcon's Fallacious Attacks on STAAR Surgical and Its Prospects
Reminds STAAR's Board That It Does Not Need Alcon's Permission to Remain Independent or Run a Proper Strategic Alternatives Process Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we") today commented on
Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
Alcon (SIX/NYSE:ALC), the global leader in eye care, today announced that it has filed an investor presentation in support of the proposed acquisition of STAAR Surgical Company (NASDAQ:STAA) with the U.S. Securities and
Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon
Questions Company's Adjournment and Postponement of the Special Meeting Without Substantive Explanation STAAR Should Heed the Strong Shareholder Opposition Already Expressed Through the Special Meeting Voting
Yunqi Capital Issues Letter to STAAR Surgical Board Opposing Adjournment of the Special Meeting and Calling for the Company to Move Beyond the Proposed Merger with Alcon
STAAR Should Not Delay the Inevitable and Should Let Shareholders Vote Company Should Not Commence a New "Go Shop" Period or Run a Rushed Sales Process Yunqi Capital Limited (together with its affiliates and the
Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction
Appalled that STAAR's Board Reneged on Its Promise to Let Shareholders Decide the Fate of the Proposed Transaction in a Timely Manner Urges STAAR to Give Up on Misbegotten Transaction and Refocus on Running the
Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders
Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced
Keybanc Maintains Overweight on Alcon, Lowers Price Target to $91
Keybanc analyst Brett Fishbin maintains Alcon with a Overweight and lowers the price target from $98 to $91.
Actions Connexes
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.